|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||2.3100 - 2.4900|
|52 Week Range||1.0500 - 3.2500|
|Beta (5Y Monthly)||1.51|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Schwazze, (OTCQX:SHWZ) ("Schwazze" or the "Company"), announced financial results for its first quarter year ended March 31, 2021 ("Q1 2021"). During the first quarter of 2021, the Company announced the completion of its acquisition of Star Buds and announced a Q1 2021 revenue increase of $19.3 million compared to $3.2 million during the same period in 2020, representing a 504% increase. Proforma revenue for the first quarter 2021 was estimated at $26.8 million, which assumes that all Star Buds had been acquired on January 1, 2021. The Company’s adjusted EBITDA was $5.8M for Q1 2021. The Company also reported positive cash flow from operations of $1.7 million compared to last year’s loss of $2.5 million.
NEW YORK, NY / ACCESSWIRE / May 13, 2021 / Medicine Man Technologies, Inc. (OTC PINK:SHWZ) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time.
Schwazze, (OTCQX:SHWZ) ("Schwazze" or the "Company"), is pleased to announce the launch of a wholly-owned research and development subsidiary, Schwazze Biosciences Ltd. While respecting the earth and environment, Schwazze Biosciences is committed to pursuing an aggressive program of basic and applied research focused on bringing consumers, as well as pets, the most beneficial properties of the cannabis plant.